title: [Immunotherapy of malignant melanoma. New prospects].
abstract: Malignant melanoma is an immunogenic tumor which can induce host humoral and cellular responses, and is a good model for development of anti-cancer immunotherapy. During the last decade systemically-administrated interferon and interleukin-2 have been used. Advances in immunology and molecular biology could allow a more specific and active immunotherapy. Perspectives include chemo-immunotherapy, monoclonal antibodies alone or in combination with cytotoxic agents, adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL), gene therapy designed to increase tumor immunogenicity, and active immunotherapy with vaccines.
authors.affiliation: Service de l'hôpital de jour, centre Oscar-Lambret, Lille, France.
authors.forename: M
authors.initials: M
authors.lastname: Hebbar
authors.forename: L
authors.initials: L
authors.lastname: Vanlemmens
authors.forename: S
authors.initials: S
authors.lastname: Lecomte
authors.forename: J
authors.initials: J
authors.lastname: Bonneterre
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology; D014611:Vaccination
vernacular_title: Immunothérapie du mélanome malin. Nouvelles perspectives.